Top

Published in:

01-05-2018 | Review Article

Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment

Authors: Massimo Breccia, Francesca Palandri, Luigiana Luciano, Giulia Benevolo, Massimiliano Bonifacio, Giovanni Caocci, Fausto Castagnetti, Giuseppe A. Palumbo, Alessandra Iurlo, Francesco Landi

Published in: Annals of Hematology | Issue 5/2018

Abstract

The incidence of cancer, including myeloproliferative neoplasms (MPNs), is projected to increase significantly due to the growing proportion of people aged > 65 years. These older individuals are a heterogeneous population in terms of fitness, comorbidity, and psychological reserve. Therefore, age per se does not always provide an accurate indication of condition in patients with cancer. Frailty has been proposed as an alternative measure of vulnerability that might better indicate which patients can tolerate standard cancer treatment and those who may benefit from treatment adjustment. A number of methods can be used to assess frailty in older patients with hematological malignancies, including the Cardiovascular Health Study Frailty Screening Measure, the FRAIL (Fatigue, Resistance, Ambulation, Illnesses, and Loss of weight) questionnaire, the Clinical Frailty Scale (CFS), and the Gérontopôle Frailty Screening Tool. In addition to physical frailty, comorbidity and quality of life should also be included in the assessment. Prior to the introduction of tyrosine kinase inhibitors (TKIs), age was considered a marker of poor prognosis in patients with MPNs. In contrast, data show that age is not necessarily a contraindication for TKI use. In CML, the efficacy of TKIs has been shown to be independent of age. The JAK1/2 inhibitor ruxolitinib also seems to be effective across a range of patient ages. Available data suggest that chronological age itself should not necessarily be a contraindication for many new therapies in patients with MPNs, and that frailty does provide a better measure of vulnerability. There is a need for specific methods to assess frailty in patients with MPNs, particularly the context of effective new treatment options, such as TKIs and ruxolitinib.

Kowal P, Dowd JE (2001) Definition of an older person. Proposed working definition of an older person in Africa for the MDS project. World Health Organization, Geneva. https://doi.org/10.13140/2.1.5188.9286

Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765. https://doi.org/10.1200/JCO.2008.20.8983 PubMedCrossRef

Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival pattern in United States (US) and medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 9(3):e90299. https://doi.org/10.1371/journal.pone.0090299 PubMedCrossRefPubMedCentral

Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukemia (CML). Best Pract Res Clin Haematol 22(3):295–302. https://doi.org/10.1016/j.beha.2009.07.007 PubMedCrossRef

Deckx L, van den Akker M, Daniels L, De Jonge ET, Bulens P, Tjan-Heijnen VC, van Abbema DL, Buntinx F (2015) Geriatric screening tools are of limited value to predict decline in functional status and quality of life: results of a cohort study. BMC Fam Pract 16(1):30. https://doi.org/10.1186/s12875-015-0241-x PubMedCrossRefPubMedCentral

Tinetti ME, Fried T (2004) The end of the disease era. Am J Med 116(3):179–185. https://doi.org/10.1016/j.amjmed.2003.09.031 PubMedCrossRef

Ommundsen N, Wyller TB, Nesbakken A, Jordhoy MS, Bakka A, Skovlund E, Rostoft S (2014) Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist 19(12):1268–1275. https://doi.org/10.1634/theoncologist.2014-0237 PubMedCrossRefPubMedCentral

Corre R, Greillier L, Le Caer H, Audigier-Valette C, Baize N, Berard H, Falchero L, Monnet I, Dansin E, Vergnenegre A, Marcq M, Decroisette C, Auliac JB, Bota S, Lamy R, Massuti B, Dujon C, Perol M, Daures JP, Descourt R, Lena H, Plassot C, Chouaid C (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. J Clin Oncol 34(13):1476–1483. https://doi.org/10.1200/JCO.2015.63.5839 PubMedCrossRef

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL (2013) Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121(21):4287–4294. https://doi.org/10.1182/blood-2012-12-471680 PubMedCrossRefPubMedCentral

10.

Breccia M, Tiribelli M, Alimena G (2012) Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84(1):93–100. https://doi.org/10.1016/j.critrevonc.2012.01.001 PubMedCrossRef

11.

European Medicines Agency (2009) Glivec: EPAR—product information. European Medicines Agency, London

12.

European Medicines Agency (2012) Jakavi: EPAR—product information. European Medicines Agency, London

13.

Russo D, Malagola M, Skert C, Fili C, Bergonzi C, Cancelli V, Cattina F (2013) Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era. Curr Cancer Drug Targets 13(7):755–767. https://doi.org/10.2174/15680096113139990090 PubMedCrossRef

14.

Abel GA, Buckstein R (2016) Integrating frailty, comorbidity, and quality of life in the management of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book 35:e337–e344. https://doi.org/10.14694/EDBK_158639 PubMedCrossRef

15.

Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380(9836):37–43. https://doi.org/10.1016/S0140-6736(12)60240-2 PubMedCrossRef

16.

Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294(6):716–724. https://doi.org/10.1001/jama.294.6.716 PubMedCrossRef

17.

Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, Mor V, Monfardini S, Repetto L, Sorbye L, Topinkova E (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241–252. https://doi.org/10.1016/j.critrevonc.2005.06.003 PubMedCrossRef

18.

Balducci L (2010) Treatment of cancer in the older aged person. Mediterr J Hematol Infect Dis 2:e2010029PubMedCrossRefPubMedCentral

19.

Luciani A, Ascione G, Bertuzzi C, Marussi D, Codeca C, Di Maria G, Caldiera SE, Floriani I, Zonato S, Ferrari D, Foa P (2010) Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 28(12):2046–2050. https://doi.org/10.1200/JCO.2009.25.9978 PubMedCrossRef

20.

Brunello A, Sandri R, Extermann M (2009) Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool. Cancer Treat Rev 35(6):487–492. https://doi.org/10.1016/j.ctrv.2009.04.005 PubMedCrossRef

21.

Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC (2012) Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 13(10):e437–e444. https://doi.org/10.1016/S1470-2045(12)70259-0 PubMedCrossRef

22.

Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R, Onder G, Marzetti E (2015) Sarcopenia as the biological substrate of physical frailty. Clin Geriatr Med 31(3):367–374. https://doi.org/10.1016/j.cger.2015.04.005 PubMedCrossRef

23.

Marzetti E, Calvani R, Cesari M, Tosato M, Cherubini A, Di Bari M, Pahor M, Savera G, Collamati A, D'Angelo E, Bernabei R, Landi F (2015) Operationalization of the physical frailty & sarcopenia syndrome: rationale and clinical implementation. Transl Med UniSa 13:29–32PubMed

24.

Cesari M, Nobili A, Vitale G (2016) Frailty and sarcopenia: from theory to clinical implementation and public health relevance. Eur J Intern Med 35:1–9. https://doi.org/10.1016/j.ejim.2016.07.021 PubMedCrossRef

25.

Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14(6):392–397. https://doi.org/10.1016/j.jamda.2013.03.022 PubMedCrossRefPubMedCentral

26.

Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091–1101. https://doi.org/10.1093/annonc/mdu540 PubMedCrossRef

27.

Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM (2015) A systematic review of factors influencing older adults’ decision to accept or decline cancer treatment. Cancer Treat Rev 41(2):197–215. https://doi.org/10.1016/j.ctrv.2014.12.010 PubMedCrossRef

28.

Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125(13):2068–2074. https://doi.org/10.1182/blood-2014-12-615187 PubMedCrossRefPubMedCentral

29.

Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM (2016) Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol 174(1):88–101. https://doi.org/10.1111/bjh.14033 PubMedCrossRef

30.

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156. https://doi.org/10.1093/gerona/56.3.M146 PubMedCrossRef

31.

Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaco Harmand M, Bergman H, Carcaillon L, Nicholson C, Scuteri A, Sinclair A, Pelaez M, Van der Cammen T, Beland F, Bickenbach J, Delamarche P, Ferrucci L, Fried LP, Gutierrez-Robledo LM, Rockwood K, Rodriguez Artalejo F, Serviddio G, Vega E, Fod-Cc group (2013) Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci 68(1):62–67. https://doi.org/10.1093/gerona/gls119 PubMedCrossRef

32.

Morley JE, Malmstrom TK, Miller DK (2012) A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 16(7):601–608. https://doi.org/10.1007/s12603-012-0084-2 PubMedCrossRefPubMedCentral

33.

Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A (2005) A global clinical measure of fitness and frailty in elderly people. Can Med Ass J 173(5):489–495. https://doi.org/10.1503/cmaj.050051 CrossRef

34.

Subra J, Gillette-Guyonnet S, Cesari M, Oustric S, Vellas B (2012) The integration of frailty into clinical practice: preliminary results from the Gerontopole. J Nutr Health Aging 16(8):714–720. https://doi.org/10.1007/s12603-012-0391-7 PubMedCrossRef

35.

Rothman MD, Leo-Summers L, Gill TM (2008) Prognostic significance of potential frailty criteria. J Am Geriatr Soc 56(12):2211–2216. https://doi.org/10.1111/j.1532-5415.2008.02008.x PubMedCrossRefPubMedCentral

36.

Purser JL, Kuchibhatla MN, Fillenbaum GG, Harding T, Peterson ED, Alexander KP (2006) Identifying frailty in hospitalized older adults with significant coronary artery disease. J Am Geriatr Soc 54(11):1674–1681. https://doi.org/10.1111/j.1532-5415.2006.00914.x PubMedCrossRef

37.

Cooper R, Kuh D, Hardy R (2010) Objectively measured physical capability levels and mortality: systematic review and meta-analysis. Br Med J 341(sep09 1):c4467. https://doi.org/10.1136/bmj.c4467 CrossRef

38.

Odden MC, Peralta CA, Haan MN, Covinsky KE (2012) Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 172(15):1162–1168. https://doi.org/10.1001/archinternmed.2012.2555 PubMedCrossRefPubMedCentral

39.

Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, Brach J, Chandler J, Cawthon P, Connor EB, Nevitt M, Visser M, Kritchevsky S, Badinelli S, Harris T, Newman AB, Cauley J, Ferrucci L, Guralnik J (2011) Gait speed and survival in older adults. JAMA 305(1):50–58. https://doi.org/10.1001/jama.2010.1923 PubMedCrossRefPubMedCentral

40.

Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, Cesari M, Donini LM, Gillette Guyonnet S, Inzitari M, Nourhashemi F, Onder G, Ritz P, Salva A, Visser M, Vellas B (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 13(10):881–889. https://doi.org/10.1007/s12603-009-0246-z PubMedCrossRef

41.

Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, Wadleigh M, Stone RM, Driver JA (2013) Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 37(9):998–1003. https://doi.org/10.1016/j.leukres.2013.05.013 PubMedCrossRefPubMedCentral

42.

Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K (2010) Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci 65:377–381PubMedCrossRef

43.

Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, Studenski S, Berkman LF, Wallace RB (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 55(4):M221–M231. https://doi.org/10.1093/gerona/55.4.M221 PubMedCrossRef

44.

Landi F, Cesari M, Calvani R, Cherubini A, Di Bari M, Bejuit R, Mshid J, Andrieu S, Sinclair AJ, Sieber CC, Vellas B, Topinkova E, Strandberg T, Rodriguez-Manas L, Lattanzio F, Pahor M, Roubenoff R, Cruz-Jentoft AJ, Bernabei R, Marzetti E, Consortium S (2017) The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: design and methods. Aging Clin Exp Res 29(1):89–100. https://doi.org/10.1007/s40520-016-0715-2 PubMedCrossRef

45.

Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, Rosti G (2014) First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 74(6):627–643. https://doi.org/10.1007/s40265-014-0207-7 PubMedCrossRef

46.

Balducci L, Dolan D (2014) Chronic myelogenous leukemia (CML) in the elderly. Mediterr J Hematol Infect Dis 6:e2014037PubMedCrossRefPubMedCentral

47.

Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105–1113. https://doi.org/10.1002/cncr.11629 PubMedCrossRef

48.

Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, Chistolini A, De Cuia R, Russo E, Salvatore GM, Biondo F, Spadea A, Mandelli F, Alimena G, Natalino F (2005) Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leukemia Res 29:287–291CrossRef

49.

Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G (2007) Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 92(1):101–105. https://doi.org/10.3324/haematol.10239 PubMedCrossRef

50.

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of oncology : official journal of the European Society for Medical Oncology 26(1):185–192. https://doi.org/10.1093/annonc/mdu490 CrossRef

51.

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomaus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Muller MC (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126(1):42–49. https://doi.org/10.1182/blood-2015-01-617993 PubMedCrossRefPubMedCentral

52.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sora F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A (2016) Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 7(48):80083–80090. https://doi.org/10.18632/oncotarget.11657 PubMedCrossRefPubMedCentral

53.

Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O’Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024–1029. https://doi.org/10.1002/ajh.23560 PubMedCrossRef

54.

Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brummendorf TH, Porkka K, Saglio G, Gastl G, Muller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ (2016) Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 30(1):57–64. https://doi.org/10.1038/leu.2015.270 PubMedCrossRef

55.

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044–1054. https://doi.org/10.1038/leu.2016.5 PubMedCrossRefPubMedCentral

56.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259. https://doi.org/10.1056/NEJMoa0912614 PubMedCrossRef

57.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENEST freedom study. Leukemia 31(7):1525–1531. https://doi.org/10.1038/leu.2017.63 PubMedCrossRefPubMedCentral

58.

Ross D, Masszi T, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre P, Martino B, Saussele S, Giles F, Radich J, Saglio G, Gopalakrishna P, Deng W, Krunic N, Bedoucha V, Hochhaus A (2017) Durable treatment-free remission (TFR) following frontline nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTFREESOM 96-WK update. Paper presented at the European Hematology Association Congress, Madrid, Spain, 22–25 June

59.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. https://doi.org/10.1182/blood-2008-07-170449 PubMedCrossRef

60.

Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392–397. https://doi.org/10.1200/JCO.2010.32.2446 PubMedCrossRef

61.

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708. https://doi.org/10.1182/blood-2009-09-245837 PubMedCrossRef

62.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798. https://doi.org/10.1056/NEJMoa1110556 PubMedCrossRef

63.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807. https://doi.org/10.1056/NEJMoa1110557 PubMedCrossRefPubMedCentral

64.

Foltz L, Palumbo A, Martino B, Palandri F, Al-Ali HK, Liberati AM, le Coutre P, Vannucchi AM, Garcia-Hernandez C, Tavares R, Griesshammer M, Gupta V, Raanani P, Giraldo P, Bouard C, Roncho JP, Khanna S, Zaritskey A (2016) Safety and efficacy of ruxolitinib for the final enrollment of JUMP: an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (n=2233). Blood 128:3107

65.

Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, investigators C-I (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047–4053. https://doi.org/10.1182/blood-2013-02-485888 PubMedCrossRef

66.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508–516. https://doi.org/10.1111/bjh.12274 PubMedCrossRefPubMedCentral

67.

Latagliata R, Di Veroli A, Palumbo GA, Bonifacio M, Andriani A, Polverelli N, Trawinska M, Tiribelli M, Anaclerico B, Benevolo G, Petriccione L, Martino B, Centra A, D’Adda M, Crugnola M, Cavazzini F, Bergamaschi M, Tieghi A, Ibatici A, Bosi C, Perricone M, Montanaro M, Cavo M, Breccia M, Vianelli N, Palandri F (2016) Efficacy and safety of ruxolitinib in elderly patients (> 75 years) with myelofibrosis. Paper presented at the American Society of Hematology 58th Annual Meeting & Exposition, San Diego, California

68.

Raanani P, Gupta V, Sadjadian P, Al-Ali HK, Giraldo P, Guglielmelli P, Foltz L, Tavares R, Zaritskey A, Bouard C, Roncho JP, Tiwari R, Martino B (2017) Safety and efficacy of ruxolitinib (RUX) in elderly patients (≥ 75 years) with myelofibrosis (MF): an analysis from the phase 3b, expanded access JUMP study paper presented at the European Hematology Association Congress, Madrid, Spain, 22–25 June

69.

Palandri F, Benevolo G, Palumbo A, Bonifacio M, Di Veroli A, Polverelli N, Andriani A, Tieghi A, Tiribelli M, Binotto G, Martino B, Petriccione L, D’Adda M, Crugnola M, Cavazzini F, Bergamaschi M, Isidori A, Trawinska M, Ibatici A, Bosi C, Sgherza N, Montanaro M, Breccia M, Sabattini E, Catani L, Vitolo U, Merli F, Aversa F, Vallisa D, Russo D, Semenzato P, Visani G, Fanin R, Cuneo A, Cavo M, Vianelli N, Latagliata R (2017) Efficacy and safety of ruxolitinib in elderly patients with myelofibrosis: a multicenter survey. Paper presented at the Italian Society of Haematology (SIE) conference, Rome, Italy, 15–18 October

70.

Breccia M, Tiribelli M, Bonifacio M, Palumbo A, Tieghi A, Polverelli N, Bergamaschi M, Cavazzini F, Isidori A, Binotto G, Cimino G, D’Adda M, Crugnola M, Bosi C, Sgherza N, Spinsanti M, Molica M, Fama A, Cerqui E, Lazzaro A, Scaffidi L, Colafigli G, Latagliata R, Fanin R, Russo D, Aversa F, Cuneo A, Cavo M, Vianelli N, Foa P, Palandri F (2017) Comorbidities and body mass index impact on survival in patients with myelofibrosis treated with ruxolitinib. Paper presented at the Italian Society of Haematology (SIE) conference, Rome, Italy, 15–18 October

71.

Polverelli N, Binotto G, Palumbo A, Bonifacio M, Breccia M, Martino B, D’Adda M, Catani L, Sabattini E, Abruzzese E, Tiribelli M, Bergamaschi M, Sgherza N, Tieghi A, Benevolo G, Cavazzini F, Isidori A, Ibatici A, Heidel F, Crugnola M, Bosi C, Latagliata R, Russo D, Cavo M, Vianelli N, Palandri F (2017) Epidemiology, outcome and risk factors for infectious complications in MF patients receiving ruxolitinib. A multicenter study on 466 patients. Paper presented at the Italian Society of Haematology (SIE) conference, Rome, Italy, 15–18 October

72.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8 PubMedCrossRef

73.

Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96(3):441–449. https://doi.org/10.3324/haematol.2010.033506 PubMedCrossRef

74.

Parmalee PA, Thuras PD, Katz IR, Lawton MP (1995) Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc 43(2):130–137. https://doi.org/10.1111/j.1532-5415.1995.tb06377.x CrossRef

75.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118(2):401–408. https://doi.org/10.1182/blood-2011-01-328955 PubMedCrossRef

76.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103. https://doi.org/10.1200/JCO.2012.42.3863 PubMedCrossRefPubMedCentral

77.

Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825–836. https://doi.org/10.1007/s11136-013-0523-5 PubMedCrossRef

Title: Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment
Authors: Massimo Breccia
Francesca Palandri
Luigiana Luciano
Giulia Benevolo
Massimiliano Bonifacio
Giovanni Caocci
Fausto Castagnetti
Giuseppe A. Palumbo
Alessandra Iurlo
Francesco Landi
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 5/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3258-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

Sleep-disordered breathing in patients with sickle cell disease

A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review

Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage